There are a myriad of musculoskeletal disease (MSD) conditions and injuries that presently have limited therapeutic options and will benefit from developing technologies in regenerative medicine. In the U.S. more than 132 million doctors office visits, 29 million emergency department, and 15 million outpatient visits are made per annum for complaints of both traumatic and chronic injuries of the musculoskeletal system.
Tissues such as muscle, cartilage, tendon, ligaments and vertebral discs show limited capacity for endogenous repair. Therefore, cellular therapies are being developed to improve the efficiency of repair or regeneration of damaged musculoskeletal structures.
We currently have two different autologous approaches for MSD indications in development:
- A proprietary methodology and cell formulation using the patients own bone marrow derived stem cells combined with an implant matrix (support system)
- A proprietary methodology and cell formulation using the patients own peripheral blood components
Our proprietary cell “kit” process (SurgWerks®) encompasses a harvesting method, and a patented smart “vision” cell purification system capable of creating a cell dose in the appropriate volume for the target treatment zone, a specialized cell enumeration and viability device, and a customized “cell-friendly” delivery system design to return the effective cell dose to the patient. The entire treatment can be completed in the doctor’s clinic in less than 30-60 minutes.
Cesca SurgWerks® Musculoskeletal Development
Avascular Necrosis (see Clinical Pipeline)
Spinal Fusion (see Clinical Pipeline)